Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis

J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):205-12. doi: 10.1177/1074248407304731.

Abstract

Multiple studies report response variability to a 300-mg clopidogrel loading dose (LD). Pooled platelet aggregometry data compared responses (change in maximal platelet aggregation [DeltaMPA] or inhibition of platelet aggregation [IPA]) to clopidogrel 300-mg (n = 131) or prasugrel 60-mg (n = 109) LDs. Poor responder rates were determined using empiric criteria (IPA < 10% and DeltaMPA < 10% for 20 microM and 5 microM adenosine diphosphate [ADP]) and Bayesian model-based criteria (IPA < 20% and DeltaMPA < 15% for 20 microM ADP; IPA < 25% and DeltaMPA < 20% for 5 microM ADP). Prasugrel achieved greater DeltaMPA and IPA from 2 to 24 hours post-LD (P < .001). For 20 microM ADP, poor responder rates for clopidogrel ranged from 17% to 43%; no prasugrel poor responders were observed. Regardless of the criterion, prasugrel 60 mg achieved greater IPA and fewer poor responders than the clopidogrel 300-mg LD.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate
  • Adolescent
  • Adult
  • Aged
  • Bayes Theorem
  • Clinical Trials, Phase I as Topic
  • Clopidogrel
  • Databases, Factual
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperazines / pharmacology*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Function Tests
  • Prasugrel Hydrochloride
  • Thiophenes / pharmacology*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology
  • Treatment Outcome

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Adenosine Diphosphate
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine